297 related articles for article (PubMed ID: 30723112)
1.
Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
[TBL] [Abstract][Full Text] [Related]
2. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
[TBL] [Abstract][Full Text] [Related]
3. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic correlates of
Sethi TK; Kovach AE; Grover NS; Huang LC; Lee LA; Rubinstein SM; Wang Y; Morgan DS; Greer JP; Park SI; Ann Thompson-Arildsen M; Yenamandra A; Vnencak-Jones CL; Reddy NM
Leuk Lymphoma; 2019 Dec; 60(12):2880-2889. PubMed ID: 31184237
[TBL] [Abstract][Full Text] [Related]
5. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
Gonzalez-Aguilar A; Idbaih A; Boisselier B; Habbita N; Rossetto M; Laurenge A; Bruno A; Jouvet A; Polivka M; Adam C; Figarella-Branger D; Miquel C; Vital A; Ghesquières H; Gressin R; Delwail V; Taillandier L; Chinot O; Soubeyran P; Gyan E; Choquet S; Houillier C; Soussain C; Tanguy ML; Marie Y; Mokhtari K; Hoang-Xuan K
Clin Cancer Res; 2012 Oct; 18(19):5203-11. PubMed ID: 22837180
[TBL] [Abstract][Full Text] [Related]
6. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma.
Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383
[TBL] [Abstract][Full Text] [Related]
7. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Kusakabe M; Nanmoku T; Suehara Y; Matsuoka R; Noguchi M; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Muratani M; Hasegawa Y; Chiba S
Cancer Sci; 2019 Jan; 110(1):401-407. PubMed ID: 30353605
[TBL] [Abstract][Full Text] [Related]
8. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
9. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
10. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL.
Cobbers JM; Wolter M; Reifenberger J; Ring GU; Jessen F; An HX; Niederacher D; Schmidt EE; Ichimura K; Floeth F; Kirsch L; Borchard F; Louis DN; Collins VP; Reifenberger G
Brain Pathol; 1998 Apr; 8(2):263-76. PubMed ID: 9546285
[TBL] [Abstract][Full Text] [Related]
11. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
[TBL] [Abstract][Full Text] [Related]
12. Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Chapuy B; Roemer MG; Stewart C; Tan Y; Abo RP; Zhang L; Dunford AJ; Meredith DM; Thorner AR; Jordanova ES; Liu G; Feuerhake F; Ducar MD; Illerhaus G; Gusenleitner D; Linden EA; Sun HH; Homer H; Aono M; Pinkus GS; Ligon AH; Ligon KL; Ferry JA; Freeman GJ; van Hummelen P; Golub TR; Getz G; Rodig SJ; de Jong D; Monti S; Shipp MA
Blood; 2016 Feb; 127(7):869-81. PubMed ID: 26702065
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
[TBL] [Abstract][Full Text] [Related]
14. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
Yamada S; Ishida Y; Matsuno A; Yamazaki K
Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].
Fu YL; Xue XM; Shen GH; Yuan LJ; Zheng B; Zhang HF; Qiu T; Huang WT
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):751-755. PubMed ID: 34405609
[No Abstract] [Full Text] [Related]
16. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
17. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
[TBL] [Abstract][Full Text] [Related]
18. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
[TBL] [Abstract][Full Text] [Related]
20. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
